Retatrutide remains an investigational medication
consultation, care, medication, supplies, shipping and support
According to the Cochrane Collaborations tool for assessing risk of bias, all trials met the criteria for low risk of bias (Additional file 1: Table S1, Fig
This is a clinical and regulatory requirement , not a DoseDirect preference
A newly released study that compared the weight loss and side effects experienced by 358 adults 65 and older who participated in trials of the drug semaglutide, or Wegovy, confirmed that seniors lost 15.5% of their body weight on average, while younger adults lost 15.6%, nearly exactly the same
Some patients may benefit from cycling the treatment (e.g., 5 days on, 2 days off) or adjusting injection timing for better results